Race Oncology

Why Invest

Updates

Announcements

Home

Inter

– Race Oncology Limited (“Race”) announces that Dr Daniel Tillett has been appointed full-time Chief Executive Officer, effective immediately. Dr Tillett will work alongside Executive Director, Dr Pete Smith, to advance the Company’s strategic, clinical and commercialisation plans for bisantrene.

● Dr Daniel Tillett appointed Chief Executive Officer of Race Oncology 

● Working closely with Executive Director, Dr Peter Smith, who will remain an Executive Director Dr Tillett will advance Race’s clinical strategy and commercialisation plans 

● Dr Tillett brings four years of previous management experience at Race Oncology and more than 25 years’ experience in the biotechnology industry